BD Biopharmaceutical Production
BD Biopharmaceutical Production
BD Biopharmaceutical Production
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
• Custom Media Program—<strong>BD</strong> has available a custom media program to meet<br />
individual customer requirements. The program offers three levels of customization,<br />
from special packaging and QC testing requirements to full formula optimization<br />
services. It is our goal to service our customers with the highest level of technical<br />
support and manufacturing flexibility.<br />
• Media Optimization Program—At the highest level of technical interaction, the<br />
Custom Media Program allows customers to outsource media optimization to <strong>BD</strong>,<br />
thus allowing them to focus resources in other critical areas. By accessing <strong>BD</strong> expertise<br />
in media development, customers can take advantage of our experience in yield<br />
enhancement and media formulation scale-up.<br />
• Dedicated animal-free equipment and environment—With the rising concerns<br />
over bovine spongiform encephalopathies and transmissible spongiform encephalopathies<br />
(BSE/TSE), <strong>BD</strong> has met the challenge by dedicating process equipment to the<br />
production of animal-free products. Specific orders can be produced in this animalfree<br />
environment.<br />
• Heightened Regulatory Compliance—<strong>BD</strong> plants are ISO 9001 and 13485<br />
Certified, and regularly inspected by the FDA to conform with our cGMP manufacturing<br />
practices. We also offer the biotherapeutic industry comprehensive programs in<br />
documenting raw material origin, manufacturing change control and Drug Master<br />
Files (DMF) for key products.<br />
History<br />
How did <strong>BD</strong> build this unmatched foundation to support the <strong>Biopharmaceutical</strong> industry?<br />
In 1955, <strong>BD</strong> acquired the Baltimore Biological Laboratory (BBL) of Baltimore, Maryland,<br />
and used its expertise to continually advance the clinical market with prepared media and<br />
diagnostic tools. In 1997, <strong>BD</strong> acquired Difco Laboratories of Detroit, Michigan. Since that<br />
acquisition, <strong>BD</strong> has merged Difco Laboratories and BBL Microbiology Systems into one<br />
division that provides customers with media, peptones, hydrolysates and extracts. Today,<br />
<strong>BD</strong> is one of the largest microbiology companies in the world, offering a broad range of<br />
microbiology and cell culture products worldwide.<br />
Difco Contributions to the <strong>BD</strong> Product Line<br />
Beginning in 1895, Difco Laboratories produced high quality enzymes, dehydrated tissues<br />
and glandular products to aid in the digestion process. The knowledge gained from<br />
processing animal tissues, purifying enzymes and performing dehydration<br />
procedures allowed a smooth transition to the preparation of dehydrated culture<br />
media, in addition to its peptones.<br />
Meat tissue and other protein digests were developed to stimulate growth of<br />
bacteria and fungi. Extensive research led to the development of Difco Bacto<br />
Peptone, which was introduced in 1914. Since then, Bacto Peptone continues<br />
to be recognized as the ‘premium quality’ standard for all other peptones.<br />
2 <strong>BD</strong> BIOPHARMACEUTICAL PRODUCTION